How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development

被引:5
|
作者
Duan, Qiongyu [1 ]
Hu, Tianyu [1 ]
Zhu, Qiuxia [1 ]
Jin, Xueying [1 ]
Chi, Feng [1 ]
Chen, Xiaodong [1 ]
机构
[1] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
mRNA; drug; targeted therapy; development; preclinical studies; WHITE BLOOD-CELLS; T-CELLS; COVID-19; VACCINE; EXPRESSION; THERAPEUTICS; DISCOVERY; DESIGN;
D O I
10.3389/fimmu.2022.974433
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
mRNA products are therapies that are regulated from the post-transcriptional, pre-translational stage of a gene and act upstream of protein synthesis. Compared with traditional small molecule drugs and antibody drugs, mRNA drugs had the advantages of simple design, short development cycle, strong target specificity, wide therapeutic field, and long-lasting effect. mRNA drugs were now widely used in the treatment of genetic diseases, tumors, and viral infections, and are expected to become the third major class of drugs after small molecule drugs and antibody drugs. The delivery system technology was the key to ensuring the efficacy and safety of mRNA drugs, which plays an important role in protecting RNA structure, enhancing targeting ability, reducing the dose of drug delivery, and reducing toxic side effects. Lipid nanoparticles (LNP) were the most common delivery system for mRNA drugs. In recent years, mRNA drugs have seen rapid development, with the number of drugs on the market increasing each year. The success of commercializing mRNA vaccines has driven a wave of nucleic acid drug development. mRNA drugs were clinically used in genetic diseases, oncology, and infectious diseases worldwide, while domestic mRNA clinical development was focused on COVID-19 vaccines, with more scope for future indication expansion.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] How far is the horizon? From current targets to future drugs in advanced renal cancer
    Stephan Kruck
    Axel S. Merseburger
    Arnulf Stenzl
    Jens Bedke
    [J]. World Journal of Urology, 2014, 32 : 69 - 77
  • [2] How far is the horizon? From current targets to future drugs in advanced renal cancer
    Kruck, Stephan
    Merseburger, Axel S.
    Stenzl, Arnulf
    Bedke, Jens
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (01) : 69 - 77
  • [3] Liposomal Drug Product Development and Quality: Current US Experience and Perspective
    Mamta Kapoor
    Sau L. Lee
    Katherine M. Tyner
    [J]. The AAPS Journal, 2017, 19 : 632 - 641
  • [4] Liposomal Drug Product Development and Quality: Current US Experience and Perspective
    Kapoor, Mamta
    Lee, Sau L.
    Tyner, Katherine M.
    [J]. AAPS JOURNAL, 2017, 19 (03): : 632 - 641
  • [5] Development of new antileishmanial drugs - current knowledge and future prospects
    Le Pape, Patrice
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2008, 23 (05) : 708 - 718
  • [6] Development of new drugs from an FDA regulatory perspective
    不详
    [J]. CLINICAL BIOCHEMISTRY, 2004, 37 (12) : 1126 - 1126
  • [7] A new perspective on the current and future development potential of ABCG1
    Zeng, Guang-Gui
    Lei, Qiong
    Jiang, Wan-Li
    Zhang, Xing-Xing
    Nie, Liluo
    Gong, Xianghao
    Zheng, Kang
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (01)
  • [8] Development of cardiovascular drugs - The US regulatory milieu from the perspective of a participating nonregulator
    Borer, JS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (12) : 2285 - 2292
  • [9] Performance evaluation of new product development from a company perspective
    Driva, H.
    Pawar, K.S.
    Menon, U.
    [J]. Integrated Manufacturing Systems, 2001, 12 (05): : 368 - 378
  • [10] New product development from past research to future applications
    Poolton, J
    Barclay, I
    [J]. INDUSTRIAL MARKETING MANAGEMENT, 1998, 27 (03) : 197 - 212